Dan Teleman is listed as an executive officer and director on 4 SEC Form D filings by 2 issuers between Jan 2012 and Feb 2026: Atox Bio Inc. (Ness Ziona, Israel (as filed: L3) — biotechnology — 2012–2019; $33M reported sold to 15 investors) and Nasus Pharma Ltd (Tel Aviv, Israel (as filed: L3) — biotechnology — 2026; $15M reported sold to 15 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 14 years. Across those companies the filings report $48M sold in total.
Listed alongside ANAT SHIRVAN (2 shared filings), CASPER BREUM (2 shared filings), DANE ROSS (2 shared filings), Daniel D Burgess (2 shared filings), ESTHER HAYUN (2 shared filings) and 19 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Dan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Dan Teleman and found 6 differences, 1 worth asking the sponsor about: Form D filed 101 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.